Abstract

This invention concerns UGT2B7 and its detoxifying ability through the glucoronidation of various drugs, including epirubicin which is used in cancer therapy. It concerns methods and compositions for determining polymorphisms in the UGT2B7 gene which enable the identification of patients at risk for toxicity effects of these drugs so that dosage and treatment regimes may be altered accordingly. It further concerns methods of treatment in which UGT2B7 substrates are administered to patients as part of a treatment regimen.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Oct 16, 2003
  • Application: Jan 25, 2002
    WO US 0202083 W
  • Priority: Jan 26, 2001
    US US 26453401 P

Sign in to the Lens

Feedback